Advertisement

Multi-institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium Histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease

      Abstract

      Objective

      To compare in a prospective nonrandomized fashion, the outcomes of collagenase clostridium histolyticum (CCH) and surgical interventions (tunical plication [TP] and partial plaque excision and grafting [PEG]) in patients with Peyronie's disease (PD). Intralesional injection of CCH is the only Food and Drug Administration-approved nonsurgical intervention for PD.

      Materials and Methods

      Between June 2015 and January 2017, 57 patients with PD and dorsal, dorsolateral, and/or lateral penile curvatures 30°-90° were included in this study. Patients with ventral curvature, hourglass deformity, and previous surgery for PD were excluded. All patients completed questionnaires and underwent penile measurements and penile vascular studies prior to and after completion of treatment, and were followed for at least 6 months.

      Results

      CCH was administered to 18 patients, TP performed in 14, and PEG in 25. The median follow-up for the whole cohort was 12 months (6-28). Mean changes in curvature after treatment were 23.3° (34.4%) for CCH, 72.0° (92.2%) for TP, and 71.8 ° (94.9%) for PEG, P<.001. Mean changes in International Index of Erectile Function-5 scores were +5.7 for CCH, +4.9 for TP, and +2.2 for PEG, P = .395. Mean penile length changes were −0.2 cm for CCH, −1.0 cm for TP, and +0.9 cm for PEG, P<.001. Three patients in the CCH group had bothersome residual curvature and underwent uneventful TP.

      Conclusion

      Surgical options are associated with superior curvature correction. CCH is an effective and safe option for motivated patients who prefer to avoid surgery. PEG is associated with a small stretched penile length gain.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Levine L
        • Burnett AL
        Standard operating procedures for Peyronie's disease.
        J Sex Med. 2013; 10: 230-244
        • Mulhall J
        • Creech SD
        • Boorjian SA
        • et al.
        Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.
        J Urol. 2004; 171: 2350-2353
        • Tal R
        • Hall MS
        • Alex B
        • et al.
        Peyronie's disease in teenagers.
        J Sex Med. 2012; 9: 302-308
        • Chung E
        • Ralph D
        • Kagioglu A
        • et al.
        Evidence-based management guidelines on Peyronie's disease.
        J Sex Med. 2016; 13: 905-923
        • Dibenedetti D
        • Nguyen D
        • Zografos L
        • et al.
        A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States.
        Adv Urol. 2011; 2011282503
        • Lindsay M
        • Schain DM
        • Grambsch
        • et al.
        The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984.
        J Urol. 1991; 146: 1007-1009
        • Stuntz M
        • Perlaky A
        • des Vignes F
        • et al.
        The prevalence of Peyronie's disease in the United States: a population-based study.
        PLoS One. 2016; 11e0150157
        • Kadioglu A
        • Kücükdurmaz F
        • Sanli O
        Current status of the surgical management of Peyronie's disease.
        Nat Rev Urol. 2011; 8: 95-106
        • Larsen S
        • Levine LA
        Review of non-surgical treatment options for Peyronie's disease.
        Int J Impot Res. 2012; 24: 1-10
        • Nelson C
        • Mulhall JP
        Psychological impact of Peyronie's disease: a review.
        J Sex Med. 2013; 10: 653-660
        • Ralph D
        • Gonzalez-Cadavid N
        • Mirone V
        • et al.
        The management of Peyronie's disease: evidence-based 2010 guidelines.
        J Sex Med. 2010; 7: 2359-2374
        • Smith J
        • Walsh TJ
        • Lue TF
        Peyronie's disease: a critical appraisal of current diagnosis and treatment.
        Int J Impot Res. 2008; 20: 445-459
        • Acikgoz A
        • Gokce E
        • Asci R
        • et al.
        Relationship between penile fracture and Peyronie's disease: a prospective study.
        Int J Impot Res. 2011; 23: 165-172
        • Mulhall J
        • Schiff J
        • Guhring P
        An analysis of the natural history of Peyronie's disease.
        J Urol. 2006; 175: 2115-2118
        • Nehra A
        • Alterowitz R
        • Culkin DJ
        • et al.
        Peyronie's disease: AUA guideline.
        J Urol. 2015; 194: 745-753
        • Gelbard M
        • Lipshultz LI
        • Tursi J
        • et al.
        Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease.
        J Urol. 2012; 187: 2268-2274
        • Gelbard M
        • Goldstein I
        • Hellstrom WJ
        • et al.
        Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.
        J Urol. 2013; 190: 199-207
        • Cordon B
        • Osmonov D
        • Hatzichristodoulou G
        • et al.
        Peyronie's penile plication.
        Transl Androl Urol. 2017; 6: 639-644
        • Chen R
        • McCraw C
        • Lewis R
        Plication procedures—excisional and incisional corporoplasty and imbrication for Peyronie's disease.
        Transl Androl Urol. 2016; 5: 318-333
        • Hatzichristodoulou G
        Grafting techniques for Peyronie's disease.
        Transl Androl Urol. 2016; 5: 334-341
        • Bella AJ
        • Beasley KA
        • Obied A
        • Brock GB
        Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique.
        Urology. 2006; 68: 852-857
        • Hatzichristodoulou G
        • Gschwend JE
        • Lahme S
        Surgical therapy of Peyronie's disease by partial plaque excision and grafting with collagen fleece: feasibility study of a new technique.
        Int J Impot Res. 2013; 25: 183-187
        • Anaissie J
        • Hellstrom WJ
        • Yafi FA
        Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a 'real world' clinical perspective.
        Drugs. 2016; 76: 1523-1528
        • Garaffa G
        • Kuehhas FE
        • De Luca F
        • et al.
        Long-term results of reconstructive surgery for Peyronie's disease.
        Sex Med Rev. 2015; 3: 113-121
        • Hatzichristodoulou G
        • Osmonov D
        • Kübler H
        • et al.
        Contemporary review of grafting techniques for the surgical treatment of Peyronie's disease.
        Sex Med Rev. 2017; 5: 544-552
        • Hellstrom W
        • Tan RBW
        • Liu G
        Safety profile of collagenase clostridium histolyticum stratified by degree of penile curvature in patients with Peyronie disease.
        Urology. 2017; 106: 237
        • DeLay K
        • Diao L
        • Nguyen HMT
        • et al.
        Successful treatment of residual curvature in Peyronie disease in men previously treated with intralesional collagenase clostridium histolyticum.
        Urology. 2017; 110: 110-113